<DOC>
	<DOCNO>NCT02513316</DOCNO>
	<brief_summary>Study I : CROMIS-2 ( AF ) Prospective cohort study patient anticoagulated cardioembolic stroke An observational inception cohort study ( n=1425 ) patient throughout United Kingdom ( UK ) - ( 79 hospital ) start best practice oral anticoagulant ( without prior use ) presume cardioembolic ischaemic stroke due non-valvular AF follow occurrence intracerebral haemorrhage ( ICH ) ischaemic stroke average two year . The main baseline exposure ( risk factor interest ) presence cerebral microbleeds ( CMBs ) magnetic resonance imaging ( MRI ) , genetic polymorphism candidate gene potential functional relevance ICH risk . Study II : CROMIS-2 ( ICH ) Observational genetics study intracerebral haemorrhage The investigator also recruit 600 patient admit participate centre ICH ( target least 300 anticoagulant-related ICH case ) collect DNA increase power genetic study . The investigator collect clinical imaging data ICH case investigate risk factor associate anticoagulant-related ICH compare non anticoagulant-related ICH .</brief_summary>
	<brief_title>Clinical Relevance Microbleeds In Stroke</brief_title>
	<detailed_description>Background Over last decade , increase use oral anticoagulant prevent cardioembolic ischaemic stroke due atrial fibrillation ( AF ) age population lead five-fold increase incidence anticoagulant-related intracranial haemorrhage ( ICH ) - rare unpredictable catastrophic complication . Cerebral microbleeds ( CMBs ) magnetic resonance imaging ( MRI ) may predict ICH risk , may genetic polymorphism influence brain small-vessel integrity anticoagulation stability . Aims To establish value CMBs genetic factor predict symptomatic ICH follow best practice oral anticoagulation prevent recurrent ischaemic stroke due AF . Methods CROMIS-2 : Study I ( AF ) - Prospective , multicentre , inception cohort study 1425 patient ischaemic stroke due AF start best practice oral anticoagulation . Patients genetic test standardized MRI include Gradient recall Echo ( GRE ) baseline , follow-up postal questionnaire ( clinical assessment medical record surveillance suspect event ) , possible person clinical assessment 2 year . The investigator compare rate symptomatic ICH CMB CMB-free patient test association plausible candidate gene . The investigator aim develop validate risk model predict symptomatic ICH follow best practice oral anticoagulation prevent recurrent ischaemic stroke due AF . CROMIS-2 : Study II ( ICH ) - An observational study ICH investigate genetic , clinical radiological risk factor associate anticoagulant-related ICH . The investigator recruit patient admit participate centre ICH ( target least 300 anticoagulant-related ICH case ) collect DNA increase power genetic study . The investigator collect clinical imaging data ICH case investigate risk factor associate anticoagulant-related ICH compare non anticoagulant-related ICH . Expected outcomes A successful predictive model ICH risk best practice oral anticoagulation AF help determine whether genetic CMB screening use clinical practice future trial . New genetic , clinical radiological risk factor associate anticoagulant-related ICH identify .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<criteria>Study I : CROMIS2 ( AF ) Inclusion criterion : Adult ( ≥18y ; upper limit ) patient clinical diagnosis nonvalvular AF ( verified ECG ) intention treat best practice oral anticoagulant ( e.g . warfarin ) Previous ischaemic stroke TIA diagnose treat clinician All patient must able GRE MRI ( within 1 week ) starting best practice oral anticoagulant Any MRI contraindication Previous use oral anticoagulation Definite contraindication oral anticoagulation Serious head injury ( result loss consciousness ) Study II : CROMIS2 ( ICH ) Inclusion criterion : • Adult ( &gt; 18y ) patient treat participate centre confirm ICH ( confirm CT MRI scan ) without history anticoagulant use time ICH Exclusion criterion : Known underlying structural cause ICH ( e.g arteriovenous malformation , tumour , cavernoma , intracranial aneurysm , haemorrhagic transformation infarct ) Major head trauma ( cause loss consciousness though sufficient cause ICH ) previous 24 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Microbleeds</keyword>
</DOC>